Skip to main content
. 2016 Mar 3;12(3):e1005454. doi: 10.1371/journal.ppat.1005454

Fig 7. In vivo protective efficacy of antibody D5.

Fig 7

Groups of mice were administered i.p. with PBS or the indicated mAbs, and one day later, inoculated i.p. with 5 × 105 TCID50 of EV71/MAV-W. The mice were monitored daily for (A) survival and (B) clinical signs for a period of 14 days. Clinical scores were graded as follows: 0, healthy; 1, reduced mobility; 2, limb weakness; 3, paralysis; 4, death. The data shown are survival rates and mean clinical scores for each group at the indicated time points. The logrank test was used to compare the survival rate between each mAb group and the PBS control group. Statistical significance is indicated as follows: n.s., P ≥ 0.05; *, P<0.05; **, P<0.01.